New Developments in Targeted Therapy for NSCLC: A Discussion With an Expert

In this series of live, 1-hour, CME/CE-certified meetings, an expert will present and discuss cases that explore the latest evidence-based recommendations for the use of targeted therapies for patients with advanced NSCLC and actionable mutations.


Oncogenic Driver Mutations in Advanced NSCLC

Molecular Testing Recommendations in Advanced NSCLC

Case: Management of a Patient With EGFR Mutation–Positive NSCLC

  • Choosing initial therapy
  • Treatment at progression

Case: Management of a Patient With ALK Translocation–Positive NSCLC

  • Initial therapy
  • Treatment at progression

Targeting Other Oncogenic Driver Mutations in Advanced NSCLC

Audience Question and Answer Session


Date / Time
Event Details


Program Director
Lyudmila Bazhenova, MD

Clinical Professor of Medicine 
Lung Cancer Unit Leader
Division of Hematology-Oncology
Department of Medicine
University of California, San Diego
San Diego, California

Program Director
Barbara Gitlitz, MD

Associate Professor of Clinical Medicine, Lung, Head and Neck Program
USC/Norris Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
Los Angeles, California

David Gerber, MD

Associate Professor
Division of Hematology-Oncology
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Sarah Goldberg, MD, MPH

Assistant Professor of Medicine (Medical Oncology)
Yale University School of Medicine
New Haven, Connecticut

Matthew Gubens, MD, MS

Assistant Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Melissa L. Johnson, MD

Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Christine M. Lovly, MD, PhD

Assistant Professor of Medicine, Division of Hematology-Oncology
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Helen J. Ross, MD

Associate Professor
Head, Thoracic Malignancies
Consultant, Medical Oncology
Division of Hematology/Medical Oncology
Department of Medicine
Mayo Clinic
Scottsdale, Arizona

Edgardo S. Santos, MD, FACP

Affiliate Associate Professor of Medicine
Florida Atlantic University
Medical Director of Cancer Research
Lynn Cancer Institute
Boca Raton Regional Hospital
Boca Raton, Florida

Conor Steuer, MD

Assistant Professor
Department of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
University of North Carolina Lineberger
Comprehensive Cancer Center
Chapel Hill, North Carolina

Anne S. Tsao, MD

Associate Professor
Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Lecia Van Dam Sequist, MD

Associate Professor of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Helena A. Yu, MD


Program Overview
This live 1-hour interactive CME/CE-certified meeting with an expert will focus on incorporating new developments in targeted therapy into the optimal care of patients with advanced NSCLC.

Goal Statement
The goal of this activity is to improve participants’ competence in optimally individualizing treatment of patients with advanced NSCLC and actionable mutations.

Target Audience
This program is intended for medical oncologists, registered nurses and other healthcare professionals who provide care for patients with advanced NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate available clinical data to the management of newly diagnosed patients with advanced-stage NSCLC and actionable mutations
  • Incorporate currently available clinical data into the management of patients with advanced-stage NSCLC and acquired resistance to targeted therapy
  • Assess emerging clinical data on new molecular markers that may affect treatment decisions for patients with advanced-stage NSCLC


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.